Clear Eyes eye drops recalled nationwide due to sterility concerns

Nearly 40,000 bottles of a popular over‑the‑counter eye drop have been removed from retail shelves across the United States after the manufacturer announced it could not confirm the product’s sterility. The recall, announced by the company on Monday, follows an internal audit that identified potential contamination risks during the manufacturing process. The affected product, sold under the brand name “ClearSight,” is used to relieve dry eye symptoms and is distributed in pharmacies, supermarkets, and online outlets.

The recall covers all batches produced between March 2023 and July 2024, with lot numbers ranging from 20230315 to 20240722. Consumers who purchased the eye drops are advised to stop use immediately and return the product to the point of purchase for a full refund. The manufacturer has stated that no adverse health effects have been reported to date, but it is urging users to seek medical attention if they experience unusual eye irritation or vision changes. The U.S. Food and Drug Administration has been notified and will monitor the situation.

This action follows a growing number of recalls in the ophthalmic product sector, prompting regulators to review sterility testing protocols for over‑the‑counter eye medications. The company has pledged to implement stricter quality controls and will provide updates as the investigation proceeds. Consumers are encouraged to check the product’s lot number against the recall list on the company’s website or the FDA’s recall portal.